{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:38:32Z","timestamp":1789501112421,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["00669806"],"award-info":[{"award-number":["00669806"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["260773"],"award-info":[{"award-number":["260773"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.yexmp.2025.105016","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T09:08:15Z","timestamp":1765444095000},"page":"105016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Stereological quantification of tumor infiltrating immune cells as predictor of immunotherapy in metastatic melanoma"],"prefix":"10.1016","volume":"145","author":[{"given":"Lenka","family":"Va\u0148kov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Pol\u00edvka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u011bra","family":"K\u0159\u00ed\u017ekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Vokurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Holubov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Pivovar\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"T\u0159e\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Kn\u00ed\u017ekov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0158\u00ed\u010da\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Ku\u010dera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pe\u0161ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2025.105016_bb0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of Ipilimumab, Nivolumab, and Pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexmp.2025.105016_bb0020","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1172\/JCI87324","article-title":"Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma","volume":"126","author":"Daud","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.yexmp.2025.105016_bb0025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","article-title":"Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma","volume":"72","author":"Erdag","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2025.105016_bb0030","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1038\/s41598-025-02597-5","article-title":"The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis","volume":"15","author":"Fu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexmp.2025.105016_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.12641","article-title":"High expression of FOXP3 in primary melanoma is associated with tumour progression","volume":"170","author":"Gerber","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0002-9440(10)63238-5","article-title":"Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions","volume":"165","author":"Gerlini","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexmp.2025.105016_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2025.105016_bb0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2025.105016_bb0060","series-title":"Unbiased Stereology: Three-Dimensional Measurement in Microscopy","author":"Howard","year":"2004"},{"key":"10.1016\/j.yexmp.2025.105016_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104181","article-title":"Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment","volume":"29","author":"Hu","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.yexmp.2025.105016_bb0070","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.yexmp.2025.105016_bb0080","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/17512433.2024.2431513","article-title":"Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity","volume":"17","author":"Justice","year":"2024","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2025.105016_bb0090","article-title":"Association of Baseline Tumor-Specific Neoantigens and CD8+ T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors","volume":"8","author":"Kerepesi","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ahe.12765","article-title":"Using virtual microscopy for the development of sampling strategies in quantitative histology and design-based stereology","volume":"51","author":"Kolinko","year":"2022","journal-title":"Anat. Histol. Embryol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.yexmp.2025.105016_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2022.07.004","article-title":"Correlation between PD-1\/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy","volume":"67","author":"Li","year":"2022","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.yexmp.2025.105016_bb0110","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2016-0013","article-title":"PD-L1 in melanoma: facts and myths","volume":"3","author":"Mandal\u00e0","year":"2016","journal-title":"Melanoma Manag."},{"key":"10.1016\/j.yexmp.2025.105016_bb0120","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bcp.14433","article-title":"Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy","volume":"86","author":"Mangan","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0125","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.3390\/cancers16122211","article-title":"Dendritic cells in shaping anti-tumor T cell response","volume":"16","author":"Mazzoccoli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.yexmp.2025.105016_bb0130","article-title":"Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0135","first-page":"128","article-title":"Melanoma epidemiology in Europe: what is new?","volume":"159","author":"Nurla","year":"2024","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.01618","volume":"41","author":"Olson","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.yexmp.2025.105016_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104774","article-title":"Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG\/TRIM","volume":"96","author":"Placke","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.yexmp.2025.105016_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70313","article-title":"Predictive significance of combined plasmatic detection of BRAF mutations and S100B tumor marker in early-stage malignant melanoma","volume":"13","author":"Polivka","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.yexmp.2025.105016_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.yexmp.2025.105016_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.yexmp.2025.105016_bb0165","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","article-title":"Risk of melanoma recurrence after diagnosis of a high-risk primary tumor","volume":"155","author":"von Schuckmann","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0175","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0180","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10637-020-01051-9","article-title":"Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors","volume":"39","author":"Sun","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.yexmp.2025.105016_bb0185","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with Nivolumab plus Relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.yexmp.2025.105016_bb0195","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","article-title":"The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma","volume":"35","author":"Uryvaev","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with Nivolumab plus Ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2025.105016_bb0205","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-18-2652","article-title":"Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma","volume":"25","author":"Wong","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2025.105016_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.0959-9673.2004.00370.x","article-title":"Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluripotency by expressing CD68 and CD163","volume":"85","author":"Woodward","year":"2004","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0215","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/ijc.31012","article-title":"The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety","volume":"141","author":"Wu","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2025.105016_bb0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canlet.2019.10.041","article-title":"PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexmp.2025.105016_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2022045956","article-title":"The novel diagnostic index based on HLA-DRB1 genotype and PD-L1 expression can predict severe irAEs in patients with metastatic melanoma taking immune checkpoint inhibitors. The results of the pilot study","volume":"42","author":"Zhukova","year":"2022","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.yexmp.2025.105016_bb0230","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00403-024-03758-8","article-title":"The tumor immune microenvironment in primary cutaneous melanoma","volume":"317","author":"Zilberg","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.yexmp.2025.105016_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome?","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat. Rev."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480025000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480025000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:38:54Z","timestamp":1783021134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480025000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"alternative-id":["S0014480025000668"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.105016","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereological quantification of tumor infiltrating immune cells as predictor of immunotherapy in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2025.105016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105016"}}